加载中
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
前收盘价
US$6.25
−US$0.16 · -2.50%
盘中时间采用ET。市场数据可能有所延迟。
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
日内区间
当前US$6.25
52周区间
当前US$6.25
盘中时间采用ET。市场数据可能有所延迟。
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
日内区间
当前US$6.25
52周区间
当前US$6.25
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 |
|---|---|---|---|
| 营收 | 1300万 USD | 700万 USD | 500万 USD |
| 销货成本 | — | 128.7万 USD | 100万 USD |
| 毛利 | 1300万 USD | 571.3万 USD | 400万 USD |
| 研究与开发 | 7404.2万 USD | 6424.4万 USD | 3199.7万 USD |
| 销售、一般及管理费用 | 2002.9万 USD | 1148.2万 USD | 985.3万 USD |
| 营业费用 | 9407.1万 USD | 7572.6万 USD | 4185万 USD |
| 利息收入 | 332.3万 USD | 324.2万 USD | 385.6万 USD |
| 利息支出 | — | 3.4万 USD | 5.8万 USD |
| 折旧和摊销 | 138.9万 USD | 128.7万 USD | 100万 USD |
| 营业利润 | −8107.1万 USD | −7001.3万 USD | −3785万 USD |
| 净利润 | −6887万 USD | −6680.8万 USD | −3405.3万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$27.83
上涨空间 345.28%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI935.66万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM254.18万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF160.21万0.00%954亿 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM97.24万0.01%64.1亿 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO92.37万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO91.97万0.01%139.17亿 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA73.09万0.00%218.24亿 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT37万0.00%220亿 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
